A study found that the use of semaglutide, a GLP-1 RA, does not increase the risk of developing NAION in patients with type 2 diabetes, obesity, or both. The study included a large, multinational, real-world population and found no significant association between semaglutide use and NAION risk over 1, 2, and 3 years of follow-up. Sensitivity analysis confirmed these findings. The study was led by Chien-Chih Chou, MD, PhD, and published in Ophthalmology. Limitations include the retrospective design and reliance on diagnosis coding. The study was supported by Taichung Veterans General Hospital, and authors reported no conflicts of interest.
Source link
Does Semaglutide Increase Risk for Optic Neuropathy?
